^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    MK-1200

    i
    Other names: MK-1200, SKB-315, SKB315
    Associations

    News

    Trials
    Company:
    Merck (MSD), Sichuan Kelun Pharma
    Drug class:
    Topoisomerase I inhibitor, CLDN18.2-targeted antibody-drug conjugate
    Related drugs:
    Associations

    News

    Trials
    26d
    Safety and Efficacy of MK-1200 in Participants With Advanced Solid Tumors (clinicaltrials.gov)
    P1/2, N=304, Recruiting, Merck Sharp & Dohme LLC | Phase classification: P2 --> P1/2 | Trial completion date: Mar 2027 --> Jan 2026 | Trial primary completion date: Jan 2027 --> Jan 2026
    Phase classification • Trial completion date • Trial primary completion date • Metastases
    |
    MK-1200
    2ms
    Safety and Efficacy of MK-1200 in Participants With Advanced Solid Tumors (clinicaltrials.gov)
    P2, N=304, Recruiting, Merck Sharp & Dohme LLC | Not yet recruiting --> Recruiting
    Enrollment open • Metastases
    |
    MK-1200
    3ms
    Safety and Efficacy of MK-1200 in Participants With Advanced Solid Tumors (clinicaltrials.gov)
    P2, N=304, Not yet recruiting, Merck Sharp & Dohme LLC
    New P2 trial • Metastases
    |
    MK-1200
    almost2years
    A Study of SKB315 in Patients With Advanced Solid Tumors (clinicaltrials.gov)
    P1, N=206, Recruiting, Sichuan Kelun Pharmaceutical Research Institute Co., Ltd.
    New P1 trial
    |
    CLDN18 (Claudin 18)
    |
    MK-1200